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OBJECTIVE: The aim of this study was to evaluate whether frequent premature ventricular contractions
originating from the right ventricular outflow tract remodel the cardiac structure and function in patients with
a ‘‘seemingly normal heart’’ and whether radiofrequency ablation can reverse this remodeling.
METHODS: Sixty-eight patients with idiopathic frequent premature ventricular contractions originating from
the right ventricular outflow tract and normal heart structure and function were enrolled in this study. The
patients were divided into three groups according to the therapeutic method: radiofrequency ablation group
(24 cases), anti-arrhythmia drug group (26 cases), and control group (18 cases without any treatment). Clinical
Registration number: ChiCTR-ONRC-12002834
RESULTS: The basic patient characteristics were comparable between the three groups, except for the premature
ventricular contraction rate, which was significantly lower in the control group. After six months of follow up, the
premature ventricular contraction rate was significantly reduced in the radiofrequency ablation group, which
was accompanied by a significant decrease in the following cardiac cavity inner diameters, as determined by
echocardiography: right atrium (33.33¡3.78 vs. 30.05¡2.60 mm, p=0.001), right ventricle (23.24¡2.40 vs.
21.05¡2.16 mm, p=0.020), and left ventricle (44.76¡4.33 vs. 41.71¡3.44 mm, p=0.025). These results were
similar in the anti-arrhythmia drug group, although this group exhibited a smaller extent of change (right atrium:
33.94¡3.25 vs. 31.27¡3.11 mm, p=0.024; right ventricle: 22.97¡3.09 vs. 21.64¡2.33 mm, p=0.049; left
ventricle: 45.92¡6.38 vs. 43.84¡5.67 mm, p=0.039), but not in the control group (p.0.05). There was a
tendency toward improvement in the cardiac functions in both the radiofrequency ablation and anti-arrhythmia
drug groups. However, these differences were not statistically significant (p.0.05).
CONCLUSIONS: These results indicate that radiofrequency ablation can potentially reverse the cardiac remodeling
caused by frequent premature ventricular contractions even in structurally normal hearts and that frequent
premature ventricular contractions should be abated even in structurally normal hearts.
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& INTRODUCTION
Arrhythmia, especially tachycardia, is commonly encoun-
tered in patients with cardiovascular disease and even in
healthy subjects (1). Persistent tachycardia can induce
dilated cardiomyopathy, and the suppression of it can
reverse the changes in cardiac structure and function in
these patients (2,3). One of tachycardia, frequent premature
ventricular contraction (FPVC), has been generally consid-
ered as benign (4), although some recent studies suggest
that long-term FPVC may cause progressive ventricular
dysfunction and dilatation and may induce dilated cardio-
myopathy (tachycardiomyopathy) or even heart failure (4-
8). The suppression of FPVCs with radiofrequency ablation
(RFA) can reduce the inner diameter of the cardiac cavity
and improve function significantly in these patients (5-9).
However, the patients in these studies have abnormal
cardiac function or cardiac cavities. Few studies have
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investigated the effect of FPVCs on the ‘‘seemingly
structurally normal heart.’’
In this study, we hypothesized that, in patients with a
normal heart, idiopathic FPVCs originating from the right
ventricular outflow tract (RVOT) may remodel the cardiac
structure and function but that RFA or anti-arrhythmia
drugs could potentially reverse this remodeling. To the best
of our knowledge, we are the first to report treatment of
patients with a normal heart with FPVCs originating from
the RVOT.
& PATIENTS
Eighty-three patients, hospitalized from September 2009
to June 2012, with RVOT-FPVCs were enrolled in this study.
The monomorphic FPVC load of these patients was more
than 10% of the total heart rate or more than 5% of the total
heart rate with ten monomorphic sustained or unsustained
ventricular tachycardia events per day (4,6). The study
population included patients with or without symptoms.
The patients with symptoms, including palpitation and
debilitation, went to the hospital with the expectation of
alleviating their symptoms. Some of the patients without
symptoms wanted to eliminate the PVCs due to their fear of
complications, whereas others did not intend to accept drug
or RFA therapy. The patients were divided into different
groups according to their treatment preference. Fifteen of
the patients were excluded due to loss during follow-up;
thus, a total of 68 patients (32 males and 36 females) with
ages ranging from 21-66 years (mean age 46.2¡14.66 years)
were enrolled in this study. These patients were divided
into three groups according to the treatment method
(Figure 1): the RFA group (n = 24) included patients who
underwent successful ablation, the AAD group (n = 26)
included patients who initially chose therapy with an anti-
arrhythmia drug (n = 24) or who initially chose ablation but
failed ablation and then chose drug therapy (n = 2), and the
control group (n = 18) included those who refused ablation
and drug therapy. In the AAD group, the patients received
0.2 g of Cordarone (Sanofi-Aventis, Hangzhou city,
Zhejiang province, China) once per day or metoprolol
succinate sustained-release tablets (AstraZeneca AB, Wuxi
city, Jiangshu province, China) at a dose of 23.75–47.5 mg
per day. If these doses were well tolerated and there were
no more than 1,000 PVCs per day (10), the doses were
continued; otherwise, the doses were increased according to
the tolerance of the patient or until there were no more than
1,000 PVCs per day (10,11).
All patients underwent extensive baseline evaluation to
rule out any structural disease. The evaluation included a
clinical history concerning the onset of symptoms, 12-lead
electrocardiography (ECG), exercise testing, 24-h Holter
monitoring, and echocardiography. Moreover, patients with
certain diseases and conditions, including rheumatic heart
disease, endocrine disease, hyperthyroidism, thyroid dys-
function, arrhythmogenic drug intake, and electrolyte
disturbances, were excluded from this study.
Antiarrhythmic drugs were discontinued for at least six
half-lives before the study. The PVC burden was evaluated
by PVC percentage, which was calculated as the number of
PVCs divided by the total number of beats in 24 h. Informed
consent forms regarding the RFA therapy and potential
complications were signed by all patients. The study
protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki as reflected in the a priori approval
by the institutional human research committee. This study
was registered with an internationally accredited site
(ChiCTR-ONRC-12002834 - http://www.chictr.org/).
& DEFINITION OF RVOT-PVC AND EVALUATION OF
CARDIAC STRUCTURE AND FUNCTION
Standard 12-lead surface ECG was performed before and
during treatment. A right ventricular outflow tract-PVC was
defined as follows: (1) PVC had a left bundle branch block
(LBBB) morphology in V1, (2) the R/S transition zones (first
precordial lead with R/S ratio $1) in the PVCs were present
in V2–V4, and (3) the R/S transition zones of the PVCs in the
precordial lead did not occur earlier than the R/S transition
zones of the sinusal QRS on the same 12-lead surface ECG.
Ventricular tachycardia was defined by standard electro-
cardiographic criteria of at least five consecutive PVCs at a
rate of more than 120 beats/min. Patients with atrial
tachyarrhythmia, including atrial fibrillation, flutter, tachy-
cardia and paroxysmal supraventricular tachycardia, were
excluded from this study because of the possibility of
tachycardia-induced LV dilation. The region of the LV
outflow tract origin was excluded from this study.
Figure 1 - Patient enrollment method.
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Cardiac structure and function were evaluated by echo-
cardiography at baseline and during follow-up according to
the ASE/ESE method (ProSounda10, ALOKA, Japan and IE-
33, Philips, Japan). Using two-dimensional and M-type
Doppler echocardiography, we measured the end diastolic
left ventricular internal diameter (normal range: 47¡4 mm),
the left atrial internal diameter (normal range: 27–40 mm),
the right basic ventricular internal diameter (normal range:
20–28 mm), the right atrial internal diameter (normal range:
29–44 mm), the inner diameter of the aorta (normal range:
,30 mm) and pulmonary artery (normal range: 12–26 mm),
the inter-ventricular septal thickness (normal range: 6–
12 mm), and the left ventricular posterior thickness (normal
range: 6–12 mm). The cardiac function parameters were also
measured, including the left ventricular ejection fraction
(LVEF, normal range: 55–80%), left ventricular fractional
shortening (LVFS, normal range: 30–45%) and E/A ratio
(normal range: .1).
& MAPPING AND CATHETER ABLATION
PROCEDURE
All procedures were performed after the signing of the
informed consent form. The patients were studied in the
fasting state without sedation. Antiarrhythmic drugs were
discontinued for at least six half-lives before the procedure.
Under local anesthesia, a 7-F deflectable quadripolar
ablation catheter (Biosense Webster, Diamond Bar,
California, USA) with a 4-mm-tip electrode was percuta-
neously introduced into the right ventricle. Based on the 12-
surface-lead electrocardiogram with spontaneous RVOT-
PVC, pace mapping was conducted using bipolar pacing
between the distal pair of the electrodes with a stimulation
pulse width of two ms. If the culprit PVCs were not found
during the procedure, isoproterenol administration and/or
programmed electrical stimulation with a digital stimulator
(LEAD 7000B, Sichuan Jinjiang Electronic Science and
technology Co., Ltd, China) was performed to induce the
PVCs as previously described (5). An optimal pace map was
defined as a match of all 12 surface leads when comparing
the R/S ratio and subtle notching in the QRS complex
during pacing. An identical match was necessary in at least
11 of 12 leads. The RFA was performed based on an optimal
pace map for 60-90 s with a preset temperature of 50-60 C˚
and a power limit of 50 Watts. A successful ablation was
defined as the non-recurrence and non-inducibility of
culprit PVCs with or without isoproterenol administration
at the rate of 0.2-0.6 mg/min and/or programmed electrical
stimulation for at least 30 min after ablation. All 12 surface
electrocardiograms and the bipolar intra-cardiac electro-
grams (filtered at 30-400 Hz) were recorded and stored
using a 48-channel acquisition system (LEAD 7000B,
Sichuan Jinjiang Electronic Science and technology Co.,
Ltd, China). During the procedure, intravenous heparin was
administered as a 100 IU/kg bolus dose followed by
additional boluses of 1,000 IU every hour. Procedural
success was defined as the lack of recurrence of culprit
PVCs within 72 h after the procedure under electrocardio-
gram monitoring.
& FOLLOW-UP
All the patients were followed up every month for the
next six months by 24-h Holter monitoring tests and the
assessment of cardiac chamber size and function.
& STATISTICAL ANALYSIS
Continuous variables are presented as the mean ¡ SD
and were compared using Student’s t-test or one-way
ANOVA. Echocardiographic measurements before and after
treatment were compared with the paired t-test. A p-value
,0.05 was considered statistically significant.
& RESULTS
General characteristics of each group
The general characteristics of each group are listed in
Table 1. In this study, the PVCs had been present for 0.5–10
years (mean 3.09¡2.61 years). The PVC rate was 8978–
36978/24 h, and 6.5–36.51% (mean 19.19¡7.41%) of the total
QRS complexes were affected. A total of six patients had
transient ventricular tachycardia (VT) (the morphology of
the VT was the same as that of the PVC, and the number of
VT events was greater 10 or the persistent time of VT was
more than 10 s). There were no differences in the age,
gender, or history of the patients with PVCs. However, the
PVC rate was higher in the RFA (19.19¡7.41%) and AAD
(18.89¡5.16%) groups compared with the control group
(13.87¡4.19%). Of the 26 patients who received RFA
therapy, 24 (92.31%) were successfully ablated. The two
unsuccessfully ablated patients were transferred to the AAD
group.
Effect of RFA on PVC burden and cardiac cavity
diameters
At the six-month follow-up, the PVC rate was only
0.05¡0.12% in the RFA group, which was lower than that in
the AAD (6.73¡5.09%) and control (13.61¡4.48%) groups.
Among the patients with PVCs in the RFA group, 21 had
less than 100 PVCs/day, two patients had 100-300 PVCs/
day, and only one patient had 561 PVCs/day. Compared
with the control group, the number of PVCs was signifi-
cantly lower in the AAD group (Table 1).
The diameters of the cardiac cavities were normal in all
three groups at baseline, and there were no significant
Table 1 - General characteristics of each group.
RFA group (n =24) AAD group (n=26) Control group (n =18)
Age (years) 45.2¡14.66 45.2¡14.66 47.7¡13.15
Gender (male:female) 11:13 12:14 9:9
PVC history (years) 3.09¡2.61 3.62¡2.07 3.02¡2.53
Basic PVC rate 19.19¡7.41% * (7.5-36.51%) 18.89¡5.16% (8.1-28.33%)* 13.87¡4.19% (6.5-20.04%)
PVC rate after
treatment
0.05¡0.12% (0-0.5%)# D 6.73¡5.09% (2.3-20.5%)# 13.61¡4.48% (7.0-21.3%)
*p,0.05 vs. control group; # p,0.05 vs. basic PVC rate; D p,0.001 vs. AAD group.
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differences between the cavities, although the diameters of
the right and left atrium and right and left ventricle were
larger in the RFA and AAD groups compared with the
control group. However, some cardiac cavity diameters
decreased significantly and were smaller in the RFA group
for 6 months follow-up (right atrium: 33.33¡3.78 mm vs.
30.05¡2.60 mm, p = 0.001; right ventricle: 23.24¡2.40 mm
vs. 21.05¡2.16 mm, p= 0.020; left ventricle: 44.76¡4.33 mm
vs. 41.71¡3.44 mm, p= 0.025). Similar results were obtained
in the AAD group for 6 months follow-up (right atrium:
33.94¡3.25 mm vs. 31.27¡3.11 mm p= 0.024; right ventricle:
22.97¡3.09 mm vs. 21.64¡2.33 mm, p = 0.049; and left
ventricle: 45.92¡6.38 mm vs. 43.84¡5.67 mm, p = 0.039).
There were no significant differences in the control group
(p.0.05) (Table 2). After treatment, the diameters of the RA,
RV, LA, and LV were significantly smaller in the RFA and
AAD groups compared with the control group (Table 2,
p,0.05), and the diameters of the RA, LA, and LV were
significantly smaller in the RFA group than in the AAD
group (Table 2, p,0.05).
To examine the changes in the cardiac cavities, we plotted
the absolute changes (Figure 2). The results indicated that the
greatest amount of RFA change occurred in the right atrium
(3.3¡0.4 mm), followed by the right ventricle (2.0¡0.2 mm)
and left ventricle (3.0¡0.22 mm), and the least amount of
change occurred in the left atrium (1.52¡0.15 mm). There
was no obvious change in the inter-ventricular septal
thickness, left ventricular posterior thickness, or inner
diameter of the aortic root and pulmonary artery. The results
were similar in the AAD group, but no significant change
was observed in the control group.
Effect of RFA on cardiac function
The examination of cardiac function indicated no sig-
nificant difference with regard to the LVFS, LVEF, and E/A
ratio between the three groups before or after treatment.
There was a tendency toward improved cardiac function in
both the RFA group (LVFS: 34.33¡4.87 vs. 36.23¡2.7
p = 0.066; LVEF: 63.71¡4.94 vs. 66.24¡6.20, p= 0.093; E/A
ratio: 1.34¡0.20 vs. 1.31¡0.14, p= 0.290) and AAD group
(LVFS: 34.42¡5.07 vs. 35.96¡4.96 p= 0.098; LVEF:
64.04¡5.45 vs. 66.13¡6.80, p= 0.133; E/A ratio: 1.36¡0.31
vs. 1.33¡0.35, p= 0.256). However, the differences were not
significant (p.0.05; Table 3).
& DISCUSSION
FPVC is one of the most common types of arrhythmia in
patients without structural heart diseases, and it is observed
in 1-4% of the general population (12). Although FPVCs can
cause palpitations, they are considered relatively benign
because of the good prognosis after long-term follow-up
(4,13). However, some recent reports undermine this popular
belief. Chugh (9) reported that, in a case of dilated
cardiomyopathy and FPVC, RFA therapy resulted in the
disappearance of the FPVCs, the return of the dilated
ventricle to a normal size, and a significant improvement in
cardiac function. Kuroki (3) observed that FPVCs increased
pulmonary venous flow regurgitation, pulmonary capillary
wedge pressure, right atrial pressure, and left ventricular
end-diastolic pressure. After ablation, these aberrant para-
meters were normalized. Yarlagadda (5) observed that the
LVEF increased to a normal level six months after successful
RFA in 27 patients with monomorphic FPVCs. Bogun (6)
found an inverse correlation between the LVEF and PVC rate
and that among 22 patients who received successful RFA and
a six-month follow-up, the LVEF increased from 0.34 to 0.59
in 18 patients but decreased from 0.34 to 0.25 in four patients.
Facchini (14) observed a subclinical but significant increase in
left ventricular dimensions in FPVC patients compared with
the control group. Because of these findings, the European
Heart Association (EHA) now includes tachycardiomyopa-
thy (TCM) caused by FPVC in their 2008 guidelines (15) and
considers it as an indication for an RFA procedure (11).
The inverse relationship between cardiac function and
PVC rate was further confirmed by Beaufort-Krol (13), who
performed a long-term follow-up of children with FPVCs
and an anatomically normal heart. The results indicated that
the PVCs originating from the left ventricle disappeared in
most patients, whereas the PVCs originating from the right
ventricle lasted to adulthood and had the possibility of
further developing into TCM. However, it was previously
unknown whether RFA therapy would have an effect on the
structurally normal hearts with FPVCs. Thus, in this study,
we enrolled patients with a structurally normal heart and
FPVCs originating from the RVOT. After RFA or AMM
treatment, cardiac cavity size was significantly decreased in
diameter, accompanied by a reduction in FPVC rate, which
may indicate the reversal of cardiac remodeling. Although
no significant difference existed between cardiac function
Table 2 - Changes in cardiac cavity diameter in each group.
Diameter of Cardiac
Cavity RFA group (n=24) AAD group (n=26) Control group (n=18)
Pre-RF Post-RF p-value Pre-treat Post-treat p-value Basic Follow-up p-value
RA (mm) 33.33¡3.78 30.05¡2.60*& 0.001 33.94¡3.25 31.27¡3.11& 0.024 32.89¡2.73 32.74¡2.49 0.251
RV (mm) 23.24¡2.40 21.05¡2.16& 0.020 22.97¡3.09 21.64¡2.33& 0.049 22.39¡2.89 22.87¡3.08 0.192
LA (mm) 33.45¡4.12 31.95¡3.06*& 0.092 32.82¡5.04 32.17¡4.36& 0.192 32.83¡3.76 32.61¡3.64 0.272
LV (mm) 44.76¡4.33 41.71¡3.44*& 0.025 45.92¡6.38 43.84¡5.67& 0.039 43.17¡3.56 43.86¡3.03 0.219
IVS (mm) 9.67¡1.66 9.71¡1.31 0.467 9.74¡1.46 9.77¡1.58 0.454 9.42¡1.18 9.49¡1.13 0.428
LVPW (mm) 8.22¡1.14 8.56¡1.28 0.201 8.19¡1.35 8.61¡1.62 0.106 8.37¡1.13 8.40¡1.14 0.472
AO (mm) 29.72¡2.67 28.95¡1.83 0.138 30.02¡3.37 29.18¡2.74 0.159 29.11¡1.99 29.50¡2.22 0.297
PA (mm) 20.62¡1.99 20.9¡1.76 0.312 20.65¡1.78 20.76¡1.85 0.251 20.89¡2.21 20.94¡2.07 0.470
*p,0.05 vs. AAD group; p,0.05 vs. control group;
The p-value in this table indicates the significance between pre-treatment and post-treatment.
RA: right atrium; RV: right ventricle; LA: left atrium; LV: left ventricle; IVS: interventricular septum; LVPW: left ventricular posterior wall; AO: aortic
opening; PO: pulmonary artery.
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before and after treatment with RFA, a tendency toward
improvement was observed. This result may indicate that
FPVCs play a remodeling role in cardiac cavities and
function and that RFA may reverse the remodeling even in
structurally normal hearts.
The fact that no significant difference was observed in
cardiac function may be attributed to the small number of
patients included in this study. Therefore, multicenter studies
with a larger group of patients who receive a long-term follow-
up investigation need to be conducted in the future. Moreover,
the absence of randomization is another limitation of this study.
Therefore, a randomized, double-blinded, and multicenter
study with long-term fellow-up is expected to be performed in
the future to confirm the results of this pilot study.
In conclusion, in patients with FPVCs originating from
the RVOT and with a structurally normal heart, RFA
reduces the FPVC rate and the size of the cardiac cavities
and has a tendency to improve cardiac function. These
results suggest that FPVCs should be reduced by RFA even
in structurally normal hearts.
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